#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 3

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Squamous cell carcinoma of skin

Recruiting

Registered drugNo placebo

Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Breast cancer+1

Recruiting

Registered drugNo placebo

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Plasma cell myeloma

Recruiting

Registered drugNo placebo

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Dexamethasone

Contact Research Centre

Hormone-refractory prostate cancer

Recruiting

Registered drugNo placebo

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate

Contact Research Centre

Polycythaemia vera

Recruiting

Registered drugNo placebo

Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carbasalate Calcium

Contact Research Centre

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Infliximab

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting

Registered drugNo placebo

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Crohn's disease

Recruiting

InvestigationalNo placebo

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:ABBV-8736

Contact Research Centre

Adenocarcinoma pancreas

Not yet recruiting

Investigational

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.